Evidence map›Paper›PMID 35698660›Full record

ArticleCommunications medicine2022

The phylodynamics of SARS-CoV-2 during 2020 in Finland.

Phuoc Truong Nguyen, Ravi Kant, Frederik Van den Broeck, Maija T Suvanto, Hussein Alburkat, Jenni Virtanen, Ella Ahvenainen, Robert Castren, Samuel L Hong, Guy Baele and 17 more

Abstract read
In one paragraph

Article in Communications medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Early unrecognised SARS-CoV-2 introductions shaped the first pandemic wave, Sweden, 2020.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
  5. Article
  6. Dispersal history of SARS-CoV-2 in Galicia, Spain.Journal of medical virology · 2024
    Article
  7. Dispersal history of SARS-CoV-2 in Galicia, Spain.medRxiv : the preprint server for health sciences · 2024
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Phuoc Truong Nguyen *Department of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-4830-4113
Ravi Kant *Department of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-3878-9775
Frederik Van den Broeck *Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID 0000-0003-2542-5585
Maija T SuvantoDepartment of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-4883-5755
Hussein AlburkatDepartment of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-7847-3762
Jenni VirtanenDepartment of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-6518-3088
Ella AhvenainenDepartment of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-1964-7811
Robert CastrenDepartment of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Samuel L HongDepartment of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID 0000-0001-6354-4943
Guy BaeleDepartment of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID 0000-0002-1915-7732
Maarit J AhavaHUS Diagnostic Center, HUSLAB, Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0001-6653-3238
Hanna JarvaHUS Diagnostic Center, HUSLAB, Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Suvi Tuulia JokirantaTranslational Immunology Research Program, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-4988-185X
Hannimari Kallio-KokkoHUS Diagnostic Center, HUSLAB, Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Eliisa KekäläinenHUS Diagnostic Center, HUSLAB, Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0001-6045-108X
Vesa KirjavainenHUS Diagnostic Center, HUSLAB, Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Elisa KortelaInfectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Satu KurkelaHUS Diagnostic Center, HUSLAB, Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Maija LappalainenHUS Diagnostic Center, HUSLAB, Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Hanna LiimatainenHUS Diagnostic Center, HUSLAB, Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Marc A SuchardDepartments of Biomathematics, Biostatistics and Human Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA USA.ORCID 0000-0001-9818-479X
Sari HannulaInstitute for Molecular Medicine Finland (FIMM), Helsinki, Finland.
Pekka EllonenInstitute for Molecular Medicine Finland (FIMM), Helsinki, Finland.
Tarja SironenDepartment of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-2344-2755
Philippe LemeyDepartment of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID 0000-0003-2826-5353
Olli VapalahtiDepartment of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-2270-6824
Teemu SmuraDepartment of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-9187-3151

Funding

Statistical Innovation to Integrate Sequences and Phenotypes for Scalable Phylodynamic InferenceR01AI153044 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Marc A. Suchard · 2021 to 2026
$2.4M
NIAID NIH HHS R01 AI153044
6 · The paper itself

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of infections and fatalities globally since its emergence in late 2019. The virus was first detected in Finland in January 2020, after which it rapidly spread among the populace in spring. However, compared to other European nations, Finland has had a low incidence of SARS-CoV-2. To gain insight into the origins and turnover of SARS-CoV-2 lineages circulating in Finland in 2020, we investigated the phylogeographic and -dynamic history of the virus. Methods: The origins of SARS-CoV-2 introductions were inferred via Travel-aware Bayesian time-measured phylogeographic analyses. Sequences for the analyses included virus genomes belonging to the B.1 lineage and with the D614G mutation from countries of likely origin, which were determined utilizing Google mobility data. We collected all available sequences from spring and fall peaks to study lineage dynamics. Results: We observed rapid turnover among Finnish lineages during this period. Clade 20C became the most prevalent among sequenced cases and was replaced by other strains in fall 2020. Bayesian phylogeographic reconstructions suggested 42 independent introductions into Finland during spring 2020, mainly from Italy, Austria, and Spain. Conclusions: A single introduction from Spain might have seeded one-third of cases in Finland during spring in 2020. The investigations of the original introductions of SARS-CoV-2 to Finland during the early stages of the pandemic and of the subsequent lineage dynamics could be utilized to assess the role of transboundary movements and the effects of early intervention and public health measures.

Indexed as

SARS-CoV-2Viral epidemiology

Identifiers

PMID35698660
PMCPMC9187640

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.